Published by linker 5
Posted on February 11, 2021
3 min readLast updated: January 21, 2026
Industry leaders must forge strategic alliances with regional players to reinforce their global presence and variegate product offerings for sustained competitive ascendancy in canine atopic dermatitis treatment market.
Global revenues of canine atopic dermatitis treatment market will surpass US$ 2.4 Bn in 2029. The growth in market value will be staggering, accredited to advancements in biotechnology, gene therapy, digital innovations, and increased investments from market players, as indicated by a new FMI report.
“Sales of canine atopic dermatitis treatment drugs and vaccines will continue to surge at an impressive rate owing to innovations in novel drug development in veterinary science. In view of enhanced resistance towards certain therapeutic agents, the demand for immune-specific vaccines and drugs is witnessing an upswing,” says the FMI analyst.
Request sample of this report at https://www.futuremarketinsights.com/reports/sample/rep-gb-4412
Key Takeaways of Canine Atopic Dermatitis Treatment Market Study
Top Growth Drivers
Key Restraints
Competitive Landscape
Leading players in global canine atopic dermatitis treatment market include, but are not limited to, Elanco Animal Health, Zoetis, Boragen Inc., and Immunomic Therapeutics Inc. Industry giants are focused on strategic alliances with regional players to boost their global presence. They continue to direct substantial resources towards regional acquisitions in order to fortify their market foothold. For instance, Zoetis acquired Nexvet Biopharma (2018) to accelerate the development of mAb therapies. This would enable the company to create new alternatives for treating canine atopic dermatitis. On the other hand, Elanco Animal Health acquired Boehringer Ingelheim Vetmedica, Inc. (2017), to innovate their range of rabies vaccines, canine and feline products.
Explore more articles in the Research Reports category
